U.S. markets closed
  • S&P Futures

    3,653.00
    -1.25 (-0.03%)
     
  • Dow Futures

    29,238.00
    -47.00 (-0.16%)
     
  • Nasdaq Futures

    11,222.50
    -5.75 (-0.05%)
     
  • Russell 2000 Futures

    1,680.20
    -1.90 (-0.11%)
     
  • Crude Oil

    81.14
    -0.09 (-0.11%)
     
  • Gold

    1,670.80
    +2.20 (+0.13%)
     
  • Silver

    18.83
    +0.12 (+0.66%)
     
  • EUR/USD

    0.9806
    -0.0013 (-0.14%)
     
  • 10-Yr Bond

    3.7470
    +0.0420 (+1.13%)
     
  • Vix

    31.84
    +1.66 (+5.50%)
     
  • GBP/USD

    1.1095
    -0.0028 (-0.25%)
     
  • USD/JPY

    144.6930
    +0.2500 (+0.17%)
     
  • BTC-USD

    19,400.44
    -53.49 (-0.27%)
     
  • CMC Crypto 200

    443.56
    -2.43 (-0.54%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    25,979.75
    -442.30 (-1.67%)
     

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

·1 min read

BRISBANE, Calif., February 28, 2022--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

  • Cowen 42nd Annual Health Care Conference
    Date: Monday, March 7th at 12:50 p.m. Eastern Time

  • Barclays Global Healthcare Conference
    Date: Thursday, March 17th at 9:00 a.m. Eastern Time

  • H.C. Wainwright & Co. Gene Editing and Therapy Conference 2022
    Date: Wednesday, March 30th at 7:00 a.m. Eastern Time

Access links for presentations, panels and fireside chats will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005783/en/

Contacts

Investor Relations & Media Inquiries
Aron Feingold
628.252.7494
afeingold@sangamo.com